Pharmaxis today announced significant headline results for the second six month dosing of its international Phase III trial of Bronchitol in people with cystic fibrosis.The lung function of patients treated with Bronchitol for a full twelve months improved from 6.5% at six months to 8.0% (p<0.001) at the end of twelve months treatment.In addition, the lung function of patients who were on placebo for the first six months of the study improved by 10.3% (p<0.001) when switched to Bronchitol.

Read Full Media Release